R
REPL
Replimune Group, Inc. Common Stock
$11.39
Current Price
1W
1M
3M
6M
1Y
All
AI analysis
Read what the AI thinks of Replimune Group, Inc. Common Stock in the app.
Analyses are generated by AI from public data and are not investment advice.
Get the app
Key figures
Dividend per share
—
Yield
—
EPS
-$3.16
P/E
—
Data as of Oct 1
Why it matters for the long term
Over 10-20 years, what drives a share up is the growth of its profits (EPS) + reinvested dividends. The P/E tells you whether you are paying a lot or a little for that growth. In short: rising EPS + reasonable P/E + growing dividend = good long-term candidate.
Upcoming events
Quarterly earnings
Expected EPS: -$0.78
Nov 4
Posts
No posts about REPL yet.
About Replimune Group, Inc. Common Stock
Replimune Group is a clinical-stage biotechnology company, meaning it has no approved products on the market yet and earns no revenue. It develops oncolytic immunotherapies, which are modified viruses designed to infect and kill cancer cells while also triggering the body's immune system to attack the tumor. Its lead program, called RP1, is being tested against advanced melanoma (a serious form of skin cancer) and other solid tumors, often paired with existing immune-boosting cancer drugs. The company funds its research by raising money from investors rather than from product sales.